News ListWednesday September 02, 2009 Next EventsIpsogen is participating to a great number of international congresses. Ipsogen’s team will be happy to meet you and discuss your current needs and find out about Ipsogen’s latest developments. ESH-CML 2009 ESH Eleventh... Category: Leukemia
 Monday August 31, 2009 Revenue for the First Half of 2009Very buoyant growth: +111% Further intensification of activity in the United States Category: Investors
 Wednesday July 15, 2009 Ipsogen further expands its offer in leukemia diagnostic, including two new JAK2 V617F detection kits and a new kit for NPM1 mutations in Acute Myeloid LeukemiaTwo new JAK2 V617F detection kits JAK2 V617F MutaSearchTM Kit: a new multiplatform kit compatible with LightCycler® 1.2 & 1.5 systems In order to better address laboratory needs, IPSOGEN developed a new JAK2 V617F detection... Category: Leukemia
Friday July 10, 2009 Ipsogen reports incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast CancerThe St Gallen Consensus Meeting specifies that Genomic Grade could be considered as an adjunct to histological grading Category: Breast Cancer
 Monday June 15, 2009 Ipsogen announces the success of a €2.5 million reserved capital increaseMarseille, June 15th 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that it has... Category: Investors
Thursday May 07, 2009 Ipsogen launches a new test to guide hormonotherapy prescription in breast cancerThe Genomic HR test will help pathologists to identify endocrine-responsive tumors that should benefit from hormonotherapy Category: Breast Cancer
Monday May 04, 2009 Ipsogen expands its US market presence through licensing agreement with ARUP Laboratories for the commercialization of JAK2 molecular diagnostic assaysMarseille, France, May 4, 2009 - IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and... Category: Leukemia
Monday April 20, 2009 Ipsogen further expands its offer in leukemia diagnostic, including a new NPM1 kit and 3 new BCR-ABL productsA new kit for NPM1 mutation A in AML NPM1 mutations are involved in about 60% of Acute Myeloid Leukemia (AML) patients with normal karyotype and represent the most specific and frequent genetic lesions described in adult de novo... Category: Leukemia
Wednesday March 18, 2009 2008 annual results in line with the Company’s development planOperating costs under control: almost stable operating loss for revenue of €4.1million, up 62.4%Cash position at end-2008: €13.33 million More Category: Investors
Sunday March 15, 2009 Ipsogen announces the CE marking of its “ProfileQuant® WT1” kitWT1 is a valuable biomarker in the prognosis and follow-up of Acute Myeloid Leukemia (AML) patients.The ProfileQuant® WT1 kit was developed and validated in the context of an international collaborative study coordinated by the... Category: Leukemia
|
|
